John D. Diekman, Ph.D. is a founder and Managing Partner of 5AM Ventures. Prior to founding 5AM, Dr. Diekman was a founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously, Dr. Diekman was Chairman and CEO of Affymetrix, Inc, where he still serves as a Director.
Dr. Diekman currently serves as Board Chairman of Ambrx and Phenomix as well as on the Boards of Directors of Igenica, Ingenuity Systems, Marcadia, and PhaseRx. He is also Vice-Chairman of Singapore's Life Science Fund, Bio*One Capital. He was recently named a Trustee of Princeton University and is also former Trustee of The California Institute of Technology and The Scripps Research Institute, where he served as Chairman. Dr. Diekman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University.